MLICM
RCKT icon

Metropolitan Life Insurance Company (MetLife)’s Rocket Pharmaceuticals RCKT Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,493
Closed -$94.1K – 1646
2024
Q1 		$94.1K Hold
3,493
– – ﹤0.01% 1078
2023
Q4 		$105K Hold
3,493
– – ﹤0.01% 1057
2023
Q3 		$71.6K Buy
3,493
+425
+14% +$7.72K ﹤0.01% 1197
2023
Q2 		$61K Buy
3,068
+168
+6% +$3.39K ﹤0.01% 1311
2023
Q1 		$49.7K Sell
2,900
-305
-10% -$5.97K ﹤0.01% 1397
2022
Q4 		$62.7K Buy
3,205
+621
+24% +$11.4K ﹤0.01% 1333
2022
Q3 		$41.2K Hold
2,584
– – ﹤0.01% 1589
2022
Q2 		$35.6K Hold
2,584
– – ﹤0.01% 1713
2022
Q1 		$41K Sell
2,584
-8,301
-76% -$143K ﹤0.01% 1710
2021
Q4 		$238K Hold
10,885
– – ﹤0.01% 1907
2021
Q3 		$325K Hold
10,885
– – ﹤0.01% 1717
2021
Q2 		$482K Buy
10,885
+653
+6% +$28.4K 0.01% 1550
2021
Q1 		$454K Sell
10,232
-384
-4% -$21.1K 0.01% 1484
2020
Q4 		$582K Hold
10,616
– – 0.01% 1263
2020
Q3 		$243K Hold
10,616
– – ﹤0.01% 1663
2020
Q2 		$222K Hold
10,616
– – ﹤0.01% 1725
2020
Q1 		$148K Hold
10,616
– – ﹤0.01% 1777
2019
Q4 		$242K Hold
10,616
– – ﹤0.01% 1782
2019
Q3 		$124K Buy
10,616
+2,519
+31% +$31.3K ﹤0.01% 2179
2019
Q2 		$121K Buy
8,097
+694
+9% +$12.1K ﹤0.01% 2207
2019
Q1 		$130K Hold
7,403
– – ﹤0.01% 2172
2018
Q4 		$110K Hold
7,403
– – ﹤0.01% 2212
2018
Q3 		$182K Buy
+7,403
New +$161K ﹤0.01% 2065

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RCKT Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Rocket Pharmaceuticals (RCKT) in Q2 2024, closing a stake of 3,493 shares — an estimated $94.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RCKT in Q3 2018 and held it in 23 quarters. The position peaked at $582K in Q4 2020. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Rocket Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,493 Rocket Pharmaceuticals shares in Q2 2024, an estimated $94.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Rocket Pharmaceuticals in Q3 2018 and held it in 23 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Rocket Pharmaceuticals position peaked at $582K in Q4 2020.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.